Clinical Report: Noninvasive Screening Model for Advanced Colorectal Neoplasia

Overview

This study developed and validated a noninvasive screening model for advanced colorectal neoplasia (ACN) using blood tumor markers and inflammatory indices. An online risk assessment tool was created, demonstrating an AUC of 0.956.

Background

Colorectal cancer is a significant health concern, often arising from advanced neoplasms. Noninvasive screening methods could enhance accessibility and compliance among patients at risk.

Data Highlights

Key Findings

• 1,290 patients were analyzed, with 210 diagnosed with advanced colorectal neoplasms.
• CEA, SII, NLR, ALB, and PLR were identified as independent predictors of ACN.
• XGBoost model achieved the highest performance with an AUC of 0.956.
• SHAP analysis indicated SII as the most influential predictor.
• The online calculator developed can assess individual risk based on blood markers.

Clinical Implications

The study presents a noninvasive approach for screening advanced colorectal neoplasia using blood markers.

Conclusion

The study presents a noninvasive approach for screening advanced colorectal neoplasia, leveraging machine learning and routine blood markers.

Related Resources & Content

1. Wehbe et al, Digestive Diseases and Sciences, 2025 -- Novel Prediction Score May Estimate Risk of Early-Onset Colorectal Cancer, Precancerous Polyps
2. Journal of Crohn's and Colitis, 2025 -- Development and validation of a risk prediction tool for the diagnosis of inflammatory bowel disease in patients presenting in primary care with abdominal symptoms
3. Evaluating the Prognostic Significance of Standard Blood Biomarkers for Three-Year Survival in Patients with Resectable Colorectal Cancer: A Clinical Nomogram Approach, 2025
4. Techniques in Coloproctology, 2024 -- A predictive nomogram utilizing inflammatory markers for assessing lymph node metastasis risk in colorectal cancer prior to surgery
5. Colorectal Cancer | American Cancer Society -- Screening Guidelines
6. Shield – P230009 | FDA -- Recently Approved Devices
7. Recommendation: Colorectal Cancer: Screening | United States Preventive Services Taskforce
8. Colorectal Cancer | American Cancer Society
9. Shield – P230009 | FDA
10. Recommendation: Colorectal Cancer: Screening | United States Preventive Services Taskforce